ESC 2019 | HOPE 4: Overcoming Obstacles to Treat Risk Factors in Developing Countries

Exhaustive intervention carried out by healthcare non-medical healthcare professionals with the support of community members resulted in a significant reduction of systolic blood pressure, LDL cholesterol levels and CAD risk in patients of Malaysia and Colombia, according to this study presented at ESC 2019 in Paris and simultaneously published in Lancet.

This intervention translated into a 11.4 mmHg reduction of systolic blood pressure and 15.6 mg/dl LDL levels compared against standard protocols.

This intervention ultimately reduced absolute risk of CAD at 10 years in 5 points.

Combining therapies that reduce hypertension and cholesterol, effectively reduce CAD risk, but access to costly medication and adherence to treatment might be poor in those that need them most.


Read also: ESC 2019 | AFIRE: Monotherapy with Rivaroxaban in Atrial Fibrillation and Stable CAD.


Focusing in 30 communities of Colombia and Malaysia, this study aimed at overcoming social barriers for effective management of risk factors in these two developing countries. Multidisciplinary intervention consisted of searching, identifying, treating and controlling risk factors by non-medical staff that visited patients in their homes or in the local healthcare center. Staff tips were clearly aligned with doctor and guideline recommendations.

In addition to advice, the program provided free antihypertensive medication (conversion enzyme inhibitors or angiotensin receptor blockers combined with a diuretic or a calcium blocker) and statins (atorvastatin 20 mg or rosuvastatin 10 mg). The team incorporated a friend or a family member to improve adherence to treatment and lifestyle.

It included a total 1371 hypertensive participants over 50 randomized to intervention with a multidisciplinary team vs. standard treatment.

Primary end point (change in cardiovascular risk at 10 years) was significantly lower in the intervention multidisciplinary arm.

Original title: A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster, randomized controlled trial.

Reference: Schwalm JD et al. Lancet. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...